Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abciximab in Acute Ischemic Stroke (AbESTT-II)
NCT00073372Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2003
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 3 trial of abciximab in ischemic stroke, sponsored by Janssen Pharmaceutical. Started Oct 2003; status: terminated.
02
Drugs
abciximab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00073372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073372.